- Home
- MGRX vs RANI Comparison
MGRX vs RANI Comparison
Compare MGRX & RANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGRX
- RANI
- Stock Information
- Founded
- MGRX 2021
- RANI 2012
- Country
- MGRX United States
- RANI United States
- Employees
- MGRX N/A
- RANI N/A
- Industry
- MGRX Computer Software: Prepackaged Software
- RANI Medicinal Chemicals and Botanical Products
- Sector
- MGRX Technology
- RANI Health Care
- Exchange
- MGRX Nasdaq
- RANI Nasdaq
- Market Cap
- MGRX 25.2M
- RANI 24.2M
- IPO Year
- MGRX 2023
- RANI 2021
- Fundamental
- Price
- MGRX $1.76
- RANI $2.21
- Analyst Decision
- MGRX
- RANI Strong Buy
- Analyst Count
- MGRX 0
- RANI 6
- Target Price
- MGRX N/A
- RANI $8.67
- AVG Volume (30 Days)
- MGRX 288.0K
- RANI 50.4M
- Earning Date
- MGRX 11-14-2025
- RANI 11-07-2025
- Dividend Yield
- MGRX N/A
- RANI N/A
- EPS Growth
- MGRX N/A
- RANI N/A
- EPS
- MGRX N/A
- RANI N/A
- Revenue
- MGRX $516,030.00
- RANI $1,200,000.00
- Revenue This Year
- MGRX N/A
- RANI N/A
- Revenue Next Year
- MGRX N/A
- RANI N/A
- P/E Ratio
- MGRX N/A
- RANI N/A
- Revenue Growth
- MGRX N/A
- RANI N/A
- 52 Week Low
- MGRX $1.32
- RANI $0.39
- 52 Week High
- MGRX $6.15
- RANI $3.87
- Technical
- Relative Strength Index (RSI)
- MGRX 39.17
- RANI 61.52
- Support Level
- MGRX $1.83
- RANI $1.42
- Resistance Level
- MGRX $2.28
- RANI $2.56
- Average True Range (ATR)
- MGRX 0.23
- RANI 0.61
- MACD
- MGRX -0.07
- RANI 0.02
- Stochastic Oscillator
- MGRX 4.35
- RANI 47.22
About MGRX Mangoceuticals Inc.
Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The company's platform provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED products.
About RANI Rani Therapeutics Holdings Inc.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.